Shantaram S. Joshi - Publications

Genetics, Cell Biology, and Anatomy University of Nebraska Medical Center, Omaha, NE, United States 
Cell Biology, Genetics, Molecular Biology, Oncology

52 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Chaturvedi NK, Mahapatra S, Kesherwani V, Kling MJ, Shukla M, Ray S, Kanchan R, Perumal N, McGuire TR, Sharp JG, Joshi SS, Coulter DW. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma. Bmc Cancer. 19: 1056. PMID 31694585 DOI: 10.1186/s12885-019-6291-z  0.6
2019 Song H, Bhakat R, Kling MJ, Coulter DW, Chaturvedi NK, Ray S, Joshi SS. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy. Biochemical and Biophysical Research Communications. PMID 31594641 DOI: 10.1016/j.bbrc.2019.09.118  0.6
2018 Chaturvedi NK, Hatch ND, Sutton GL, Kling M, Vose JM, Joshi SS. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib. Leukemia & Lymphoma. 1-10. PMID 30424705 DOI: 10.1080/10428194.2018.1520986  0.64
2018 Chaturvedi NK, Kling MJ, Coulter DW, McGuire TR, Ray S, Kesherwani V, Joshi SS, Sharp JG. Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. Oncotarget. 9: 16619-16633. PMID 29682173 DOI: 10.18632/oncotarget.24618  0.6
2017 Ray S, Coulter DW, Gray SD, Sughroue JA, Roychoudhury S, McIntyre EM, Chaturvedi NK, Bhakat KK, Joshi SS, McGuire TR, Sharp JG. Suppression of STAT3 NH2 -Terminal Domain Chemosensitizes Medulloblastoma Cells by Activation of Protein Inhibitor of Activated STAT3 via de-repression by MicroRNA-21. Molecular Carcinogenesis. PMID 29280516 DOI: 10.1002/mc.22778  0.6
2016 Coulter DW, McGuire TR, Sharp JG, McIntyre EM, Dong Y, Wang X, Gray S, Alexander GR, Chatuverdi NK, Joshi SS, Chen X, Vennerstrom JL. Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513. Bmc Cancer. 16: 867. PMID 27821095 DOI: 10.1186/s12885-016-2872-2  0.44
2016 Hassan HM, Varney ML, Chaturvedi NK, Joshi SS, Weisenburger DD, Singh RK, Dave BJ. Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status. Leukemia & Lymphoma. 1-16. PMID 27074052 DOI: 10.3109/10428194.2016.1165814  0.64
2016 Chaturvedi NK, McGuire TR, Coulter DW, Shukla A, McIntyre EM, Sharp JG, Joshi SS. Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan. Oncotarget. PMID 26934655 DOI: 10.18632/oncotarget.7714  0.64
2016 Shukla A, Rai K, Shukla V, Chaturvedi NK, Bociek RG, Pirruccello SJ, Band H, Lu R, Joshi SS. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. Blood. PMID 26809508 DOI: 10.1182/blood-2015-09-669317  0.64
2015 Shukla A, Cutucache CE, Sutton GL, Pitner MA, Rai K, Rai S, Opavsky R, Swanson PC, Joshi SS. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model. Experimental Hematology. PMID 26435347 DOI: 10.1016/j.exphem.2015.09.005  0.64
2014 Chaturvedi NK, Mir RA, Band V, Joshi SS, Guda C. Experimental validation of predicted subcellular localizations of human proteins. Bmc Research Notes. 7: 912. PMID 25510246 DOI: 10.1186/1756-0500-7-912  0.64
2014 Mittal AK, Chaturvedi NK, Rai KJ, Gilling-Cutucache CE, Nordgren TM, Moragues M, Lu R, Opavsky R, Bociek GR, Weisenburger DD, Iqbal J, Joshi SS. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease. Molecular Medicine (Cambridge, Mass.). 20: 290-301. PMID 24800836 DOI: 10.2119/molmed.2012.00303  0.64
2013 Chaturvedi NK, Rajule RN, Shukla A, Radhakrishnan P, Todd GL, Natarajan A, Vose JM, Joshi SS. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Molecular Cancer Therapeutics. 12: 2006-17. PMID 23963361 DOI: 10.1158/1535-7163.MCT-13-0239  0.64
2013 Mittal AK, Chaturvedi NK, Rohlfsen RA, Gupta P, Joshi AD, Hegde GV, Bociek RG, Joshi SS. Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. Plos One. 8: e70352. PMID 23936412 DOI: 10.1371/journal.pone.0070352  0.64
2013 Shukla V, Ma S, Hardy RR, Joshi SS, Lu R. A role for IRF4 in the development of CLL. Blood. 122: 2848-55. PMID 23926303 DOI: 10.1182/blood-2013-03-492769  0.64
2013 Ma S, Shukla V, Fang L, Gould KA, Joshi SS, Lu R. Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4. The Journal of Biological Chemistry. 288: 26430-40. PMID 23897826 DOI: 10.1074/jbc.M113.475913  0.64
2013 Peters HL, Yan Y, Nordgren TM, Cutucache CE, Joshi SS, Solheim JC. Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells. Cancer Biology & Therapy. 14: 752-60. PMID 23792571 DOI: 10.4161/cbt.25183  0.64
2012 Gilling CE, Mittal AK, Chaturvedi NK, Iqbal J, Aoun P, Bierman PJ, Bociek RG, Weisenburger DD, Joshi SS. Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1. British Journal of Haematology. 158: 216-31. PMID 22571278 DOI: 10.1111/j.1365-2141.2012.09148.x  0.64
2012 Ahrens AK, Chaturvedi NK, Nordgren TM, Dave BJ, Joshi SS. Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from different tissue sites. Leukemia & Lymphoma. 53: 2269-78. PMID 22568512 DOI: 10.3109/10428194.2012.691481  0.64
2012 Hegde GV, Nordgren TM, Munger CM, Mittal AK, Bierman PJ, Weisenburger DD, Vose JM, Sharp JG, Joshi SS. Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling. International Journal of Cancer. Journal International Du Cancer. 131: 2951-60. PMID 22511234 DOI: 10.1002/ijc.27602  0.64
2012 Munger CM, Hegde GV, Weisenburger DD, Vose JM, Joshi SS. Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma. Cancer Immunology, Immunotherapy : Cii. 61: 1819-32. PMID 22441656 DOI: 10.1007/s00262-012-1229-1  0.64
2011 Kollessery G, Nordgren TM, Mittal AK, Joshi SS, Sanderson SD. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model. Vaccine. 29: 5904-10. PMID 21723901 DOI: 10.1016/j.vaccine.2011.06.070  0.64
2010 Clark EM, Joshi DS, Grimm AB, Joshi AD, Wang P, Joshi SS. Ultrastructural basis of enhanced antitumor cytotoxicity of cord blood-derived CTLs: a comparative analysis with peripheral blood and bone marrow. International Journal of Oncology. 37: 645-53. PMID 20664933 DOI: 10.3892/ijo-00000713  0.64
2008 Hegde GV, Peterson KJ, Emanuel K, Mittal AK, Joshi AD, Dickinson JD, Kollessery GJ, Bociek RG, Bierman P, Vose JM, Weisenburger DD, Joshi SS. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Molecular Cancer Research : McR. 6: 1928-36. PMID 19074837 DOI: 10.1158/1541-7786.MCR-08-0142  0.64
2008 Joshi SS, Mittal AK, Wang P, Joshi AD, Vu E, Wang X. Differential gene expression in murine large cell B-cell lymphoma metastatic variants. International Immunopharmacology. 8: 1257-63. PMID 18602072 DOI: 10.1016/j.intimp.2008.05.007  0.64
2008 Hegde GV, Munger CM, Emanuel K, Joshi AD, Greiner TC, Weisenburger DD, Vose JM, Joshi SS. Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma. Molecular Cancer Therapeutics. 7: 1450-60. PMID 18524848 DOI: 10.1158/1535-7163.MCT-07-2118  0.64
2008 Hegde GV, Meyers-Clark E, Joshi SS, Sanderson SD. A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells. International Immunopharmacology. 8: 819-27. PMID 18442785 DOI: 10.1016/j.intimp.2008.01.031  0.64
2007 Joshi AD, Clark EM, Wang P, Munger CM, Hegde GV, Sanderson S, Dave HP, Joshi SS. Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 2: 202-12. PMID 18040845 DOI: 10.1007/s11481-006-9038-y  0.64
2007 Reddy MK, Vasir JK, Hegde GV, Joshi SS, Labhasetwar V. Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury. Journal of Cardiovascular Pharmacology and Therapeutics. 12: 237-47. PMID 17875952 DOI: 10.1177/1074248406297326  0.64
2007 Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy JD, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose JM, Joshi SS. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5295-304. PMID 17875758 DOI: 10.1158/1078-0432.CCR-07-0283  0.64
2007 Mittal AK, Hegde GV, Aoun P, Bociek RG, Dave BJ, Joshi AD, Sanger WG, Weisenburger DD, Joshi SS. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. International Journal of Molecular Medicine. 20: 461-9. PMID 17786276  0.64
2007 Joshi AD, Dickinson JD, Hegde GV, Sanger WG, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose JM, Joshi SS. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion. Cancer Genetics and Cytogenetics. 172: 120-6. PMID 17213020 DOI: 10.1016/j.cancergencyto.2006.07.010  0.64
2006 Chakravarti D, Zahid M, Backora M, Myers EM, Gaikwad N, Weisenburger DD, Cavalieri EL, Rogan EG, Joshi SS. Ortho-quinones of benzene and estrogens induce hyperproliferation of human peripheral blood mononuclear cells. Leukemia & Lymphoma. 47: 2635-44. PMID 17169809 DOI: 10.1080/10428190600931937  0.64
2006 Munger CM, Vose JM, Joshi SS. Dendritic cell-based therapy for mantle cell lymphoma. International Journal of Oncology. 28: 1337-43. PMID 16685434  0.64
2006 Dickinson JD, Joshi A, Iqbal J, Sanger W, Bierman PJ, Joshi SS. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect. International Journal of Molecular Medicine. 17: 769-78. PMID 16596259  0.44
2006 Dickinson JD, Gilmore J, Iqbal J, Sanger W, Lynch JC, Chan J, Bierman PJ, Joshi SS. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leukemia & Lymphoma. 47: 231-44. PMID 16321852 DOI: 10.1080/10428190500254141  0.44
2005 Dickinson JD, Smith LM, Sanger WG, Zhou G, Townley P, Lynch JC, Pavletic ZS, Bierman PJ, Joshi SS. Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia. British Journal of Haematology. 128: 460-71. PMID 15686453 DOI: 10.1111/j.1365-2141.2004.05344.x  0.64
2004 Wang P, Munger CM, Joshi AD, Pirruccello SJ, Joshi SS. Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo. Breast Cancer Research and Treatment. 83: 15-23. PMID 14997051 DOI: 10.1023/B:BREA.0000010688.55353.a8  0.64
2003 Pavletic SZ, Bociek RG, Foran JM, Rubocki RJ, Kuszynski CA, Wisecarver JL, Hatcher L, Lucas DM, Byrd JC, Grever MR, Joshi SS, Hardiman P, Smith LM, McGuire TR, Bierman PJ, et al. Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. Transplantation. 76: 877-81. PMID 14501873 DOI: 10.1097/01.TP.0000084869.08639.A0  0.64
2002 Wang P, Pavletic ZS, Joshi SS. Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation. Leukemia & Lymphoma. 43: 1827-35. PMID 12685840 DOI: 10.1080/1042819021000006411  0.64
2002 Joshi SS, Vu UE, Lovgren TR, Lorkovic M, Patel W, Todd GL, Kuszynski C, Joshi BJ, Dave HP. Comparison of phenotypic and functional dendritic cells derived from human umbilical cord blood and peripheral blood mononuclear cells. Journal of Hematotherapy & Stem Cell Research. 11: 337-47. PMID 11983105 DOI: 10.1089/152581602753658529  0.64
2001 Joshi SS, Lovgren TR, Wang P, Tarantolo SR. Generation of cytokine activated antigen non-specific and dendritic cell primed Her2/neu peptide specific cytotoxic T cells from cord blood against human breast cancer Breast Cancer Research and Treatment. 69: 311.  0.64
2000 Vu UE, Pavletic ZS, Wang X, Joshi SS. Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use. Leukemia & Lymphoma. 39: 573-82. PMID 11342340 DOI: 10.3109/10428190009113387  0.64
2000 Liu C, Ferdinandi ES, Ely G, Joshi SS. Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts. International Journal of Oncology. 16: 1015-20. PMID 10762639  0.64
1997 Hao W, Messbarger L, Joshi SS. Immunosuppression by metastatic lymphoma derived altered retroviral gp70 molecule. Leukemia. 11: 202-5. PMID 9209341  0.64
1995 Joshi SS, Connolly J, Mann SL, Sharp JG. Altered in vivo and in vitro behavior of butanol-modified bone marrow cells. Experimental Hematology. 23: 1284-8. PMID 7589283  0.64
1995 Verbik DJ, Joshi SS. Immune cells and cytokines: Their role in cancer immunotherapy International Journal of Oncology. 7: 205-223.  0.64
1994 Joshi SS, Messbarger LJ, Hao W. Interleukin-2 therapy of lymphoma-bearing immunosuppressed mice. Clinical & Experimental Metastasis. 12: 37-46. PMID 8287619 DOI: 10.1007/BF01784332  0.64
1991 Gabius S, Joshi SS, Gabius HJ, Sharp JG. Establishment, characterization and determination of cell surface sugar receptor (lectin) expression by neoglycoenzymes of a human myeloid marker-expressing B lymphoblastoid cell line. Anticancer Research. 11: 793-800. PMID 1712180  0.64
1990 Mirvish SS, Weisenburger DD, Joshi SS, Nickols J. 2-Hydroxyethylnitrosourea induction of B cell lymphoma in female Swiss mice. Cancer Letters. 54: 101-6. PMID 2208085 DOI: 10.1016/0304-3835(90)90098-I  0.64
1990 Hao WM, Joshi SS. Differential susceptibility of metastatic lymphoma cells to natural immunity. Oncology. 47: 483-7. PMID 2123024  0.64
1990 Joshi SS, Brunson KW. Differential cell surface antigen expression on metastatic variant lymphoma cell lines. Oncology. 47: 339-43. PMID 1694982 DOI: 10.1159/000226845  0.64
Show low-probability matches.